Core Viewpoint - Tianjin Development (00882) expects its indirect non-wholly-owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical), to achieve a net profit attributable to shareholders of the listed company of 400 million to 440 million yuan for the fiscal year 2025, representing a significant increase of 116.77% to 138.44% compared to the previous year's profit of 185 million yuan [1] Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 160 million to 190 million yuan, up from 103 million yuan in the previous year, indicating a growth of 55.34% to 84.47% [1] - Basic earnings per share are expected to be between 1.50 yuan and 1.80 yuan [1] Market Expansion - The company has been increasing its market expansion efforts, leading to improved product sales [1] - The significant year-on-year increase in net profit is also influenced by dividend factors from Tianjin Tasly Biological Pharmaceutical Industry Group Co., Ltd. [1]